No quarterly revenue total was found in RELMADA THERAPEUTICS, INC.'s SEC filings.
Relmada Therapeutics, Inc. (RLMD) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-12.91M
-30.9% vs year-ago quarter
Operating cash flow
$-9.61M
-50.1% vs year-ago quarter
Free cash flow
—
EPS
$-0.11
+63.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
106.67M
+221.4% vs year-ago quarter
Net cash
—
Operating margin
-1558.7%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RLMD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Coral Gables, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1553643
- Former names
- CAMP NINE, INC. (until Jul 14, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$15.0M | -$19.5M | -$20.3M | -$10.3M | -$10.2M |
| Net income | -$12.9M | -$19.1M | -$19.9M | -$10.1M | -$9.9M |
| Diluted EPS | -$0.11 | -$0.22 | -$0.33 | -$0.30 | -$0.30 |
| Operating cash flow | -$9.6M | -$15.1M | -$14.6M | -$6.7M | -$6.4M |
| Total assets | $219.1M | $235.4M | $94.0M | $14.9M | $21.1M |
| Total liabilities | $12.5M | $16.6M | $7.5M | $5.4M | $5.2M |
| Stockholders' equity | $206.6M | $218.7M | $86.5M | $9.5M | $15.9M |
| Cash and investments | $217.7M | $234.0M | $93.0M | $13.9M | $20.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 8, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 28, 2026 | May 27, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 12, 2026 | May 12, 2026 |
All 606 Relmada Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.